SMS Pharma Board Approves FY26 Results, Recommends 40% Dividend, Shifts Office
SMS Pharmaceuticals Limited reported audited financial results for FY26. The company recommended a final dividend of 40% (Re. 0.40 per share). The registered office will be shifted effective May 25, 2026. Cost and Internal Auditors were appointed for FY27. The Board meeting concluded on May 22, 2026.
The announcement includes the declaration of financial results and a dividend recommendation, which are material to investors. The shifting of the registered office is a significant operational change.
The announcement reports financial results and corporate actions. While the results show growth, the dividend recommendation and office shift are standard corporate procedures, leading to a neutral sentiment.
SMS Pharmaceuticals Limited announced its audited financial results for the fourth quarter and the full financial year ended March 31, 2026. The Board of Directors, in its meeting held on May 22, 2026, approved these results, which received an unmodified opinion from the statutory auditors.
The company recommended a final dividend of Re. 0.40 per equity share (40%) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Furthermore, the Board approved the shifting of the company's registered office from Banjara Hills, Hyderabad, to Kondapur, Hyderabad, effective May 25, 2026.
In other key decisions, M/s. Annapragada & Co. were appointed as Cost Auditors for FY 2026-27, and M/s. Adusumilli & Associates were re-appointed as Internal Auditors for the same period.
The financial results indicate a total income of ₹89,522.48 lakhs for the year ended March 31, 2026, compared to ₹78,897.25 lakhs in the previous year. Net profit after tax for the year stood at ₹8,760.93 lakhs (standalone) and ₹8,799.79 lakhs (consolidated). The board meeting commenced at 10:30 AM and concluded at approximately 01:35 PM.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.